Fused heterocycles as RIPK1 inhibitors

Novel heterocyclic compounds targeting RIP1 kinase address the limitations of current inhibitors by offering improved specificity and efficacy in treating RIPK1-mediated diseases, including inflammatory and autoimmune disorders, and cancers.

JP2024545552AActive Publication Date: 2024-12-10BISICHEM CO LTD
5 Cites -1 Cited by

Patent Information

Application Number
JP2024517518
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-09-17
Filing Date
2022-09-18
Publication Date
2024-12-10
Estimated Expiration
2042-09-18

Smart Images

  • Figure 2024545552000001_ABST
    Figure 2024545552000001_ABST
Patent Text Reader

Abstract

The present invention provides novel substituted heterocycles represented by formula I, or pharma- ceutically acceptable salts, solvates, polymorphs, esters, tautomers or prodrugs thereof, and compositions comprising such compounds. The provided compounds can be used as inhibitors and methods of treatment of RIPK1. [Formula 1] JPEG2024545552000127.jpg3587
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Heterocyclic compound and salt thereof, preparation method, application and medicine

    CN109134448A

  • Heterocyclic amides as kinase inhibitors

    JP2016512488A

  • Compounds, compositions and methods

    JP2019508407A

  • Fused ring heteroaryl compounds as RIPK1 inhibitors

    WO2021029632A1

  • Rip1 inhibitory compounds and methods for making and using the same

    WO2021046407A1